<- Go home

Added to YB: 2025-10-02

Pitch date: 2025-09-30

CPH.TO [bullish]

Cipher Pharmaceuticals Inc.

+25.44%

current return

Author Info

Rorschach Stocks is a current NFL athlete documenting my investment portfolio and ideas. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 15.25

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

growth

Show full summary:
A Real Head Scratcher... Cipher Pharmaceuticals Inc.

CPH.TO: Canadian pharma co w/ 40% insider ownership, 77% gross margins on $47.6M rev (+122% YoY). Natroba acquisition ($80M) transformational - 84% margins, 60% of rev, market share gains vs ineffective permethrin. Trading low teens FCF multiple despite runway for growth via Canada launch & int'l licensing.

Read full article (5 min)